Now showing items 1-4 of 4

    • BORIS Promotes Chromatin Regulatory Interactions in Treatment-Resistant Cancer Cells 

      Dries, Ruben; Seruggia, Davide; Gao, Yang; Sharma, Bandana; Huang, Hao; Moreau, Lisa; McLane, Michael; Marco, Eugenio; Chen, Ting; Yuan, Guo-Cheng; Young, Richard A.; Debruyne, David; Day, Daniel; Gray, Nathanael; Wong, Kwok-Kin; Orkin, Stuart; George, Rani; Sengupta, Satyaki (Springer Science and Business Media LLC, 2019-08)
      The CCCTC-binding factor (CTCF), which anchors DNA loops that organize the genome into structural domains, plays a central role in gene control by facilitating or constraining interactions between genes and their regulatory ...
    • CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma 

      Cai, Yi; Hirata, Ayako; Nakayama, Sohei; VanderLaan, Paul A.; Levantini, Elena; Yamamoto, Mihoko; Hirai, Hideyo; Wong, Kwok-Kin; Costa, Daniel B.; Watanabe, Hideo; Kobayashi, Susumu S. (Public Library of Science, 2015)
      Lung cancer is the leading cause of cancer death worldwide. Although disruption of normal proliferation and differentiation is a vital component of tumorigenesis, the mechanisms of this process in lung cancer are still ...
    • EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors 

      Fillmore, Christine M.; Xu, Chunxiao; Desai, Pooja T.; Berry, Joanne M.; Rowbotham, Samuel P.; Lin, Yi-Jang; Zhang, Haikuo; Marquez, Victor E.; Hammerman, Peter S.; Wong, Kwok-Kin; Kim, Carla F. (2014)
      SUMMARY Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide1. Chemotherapies such as the topoisomerase II inhibitor (TopoIIi) etoposide effectively reduce disease in a minority of NSCLC ...
    • Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors 

      Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Jänne, Pasi A.; Eck, Michael J. (2016)
      EGFR tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harboring activating mutations in the EGFR kinase1,2, but resistance arises rapidly, most ...